Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Melanie M. Frigault"'
Autor:
Priti Patel, Raquel Izumi, Cheng Quah, Bruce D. Cheson, John N. Allan, Morton Coleman, Thomas J. Kipps, Dan Jones, Min Hui Wang, Philip A. Thompson, Melanie M. Frigault, Rakesh K. Raman, Jeff P. Sharman, Kerry A. Rogers
Publikováno v:
Haematologica
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Autor:
John C. Byrd, Raquel Izumi, Min Hui Wang, David M. Weiss, Cheng Quah, Veerendra Munugalavadla, Seema A. Bhat, Michael Gulrajani, Melanie M. Frigault, James S. Blachly, Gerard Lozanski, Mojgan Jianfar, Kerry A. Rogers, Barbara L. Andersen, Jennifer A. Woyach, Ahmed Hamdy
Publikováno v:
Cancer Discov
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23162eb0f19e1b3d22d3d6fb6fa3ae62
https://europepmc.org/articles/PMC8176161/
https://europepmc.org/articles/PMC8176161/
Autor:
Raquel Izumi, Kerry A. Rogers, Morton Coleman, Cheng Quah, Rakesh K. Raman, Bruce D. Cheson, Jeff P. Sharman, Philip A. Thompson, Melanie M. Frigault, Min Hui Wang, John N. Allan, Thomas J. Kipps
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S282-S283
Autor:
Priti Patel, Jennifer A. Woyach, Raquel Izumi, Richard R. Furman, Peter Hillmen, Ahmed Hamdy, Prista Charuworn, Jennifer R. Brown, Elena Bibikova, John M. Pagel, Deborah M. Stephens, Min Hui Wang, Farrukh T. Awan, Bolan Linghu, Melanie M. Frigault, Anna Schuh, John C. Byrd
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc6bd1edf0ce7856814aa1698875621
https://europepmc.org/articles/PMC6517672/
https://europepmc.org/articles/PMC6517672/
Autor:
Kerry A. Rogers, Raquel Izumi, Jeff Porter Sharman, Rakesh Raman, Thomas J. Kipps, Morton Coleman, Philip A. Thompson, Min Hui Wang, Cheng Seok Quah, John N. Allan, Bruce D. Cheson, Melanie M. Frigault
Publikováno v:
Journal of Clinical Oncology. 37:7530-7530
7530 Background: In CLL pts treated with the Bruton tyrosine kinase (BTK) inhibitor IBR, the most common reason for discontinuation was adverse events (AEs; 50%-63%; Mato et al, 2018). This Phase 2 trial evaluated acalabrutinib, a highly selective, p
Publikováno v:
Blood. 132:3139-3139
Background: Chronic lymphocytic leukemia (CLL) development is associated with global immunodeficiency including T-cell exhaustion. We hypothesise that repairing T cell functions would improve outcome and decrease infectious complications which cause